Fabio Blandini

List of Publications by Citations

157 papers	6,075 citations	42 h-index	70 g-index
168 ext. papers	6,997 ext. citations	4.9 avg, IF	5.96 L-index

#	Paper	IF	Citations
157	Functional changes of the basal ganglia circuitry in Parkinson's disease. *Progress in Neurobiology*, **2000**, 62, 63-88	10.9	413
156	Animal models of Parkinson's disease. *FEBS Journal*, **2012**, 279, 1156-66	5.7	269
155	Glutamate and Parkinson's disease. *Molecular Neurobiology*, **1996**, 12, 73-94	6.2	258
154	The 6-hydroxydopamine model: news from the past. *Parkinsonism and Related Disorders*, **2008**, 14 Suppl 2, S124-9	3.6	206
153	Locus coeruleus and neuronal plasticity in a model of focal limbic epilepsy. *Epilepsia*, **2006**, 47 Suppl 5, 21-5	6.4	145
152	Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. *European Journal of Neuroscience*, **2007**, 25, 397-405	3.5	134
151	A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease. *Journal of Neural Transmission*, **2014**, 121, 849-59	4.3	123
150	Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. *Cell Transplantation*, **2010**, 19, 203-17	4	117
149	Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. *Headache*, **1990**, 30, 705-9	4.2	116
148	Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. *Brain Research*, **2010**, 1311, 12-27	3.7	112
147	Neural and immune mechanisms in the pathogenesis of Parkinson's disease. *Journal of NeuroImmune Pharmacology*, **2013**, 8, 189-201	6.9	109
146	Parkinson's Disease in Women and Men: What's the Difference?. *Journal of Parkinsonis Disease*, **2019**, 9, 501-515	5.3	104
145	Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. *Experimental Neurology*, **2004**, 187, 455-9	5.7	100
144	Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. *Journal of Neuroinflammation*, **2018**, 15, 205	10.1	98
143	Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. *Neurobiology of Disease*, **2008**, 29, 161-8	7.5	90
142	Plasma Homocysteine and l-DOPA Metabolism in Patients with Parkinson Disease. *Clinical Chemistry*, **2001**, 47, 1102-1104	5.5	86
141	Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. *Neurobiology of Disease*, **2006**, 22, 1-9	7.5	84

140	SOD1 and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegeneration. *Oxidative Medicine and Cellular Longevity*, **2013**, 2013, 836760	6.7	79
139	Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment. *Acta Neurologica Scandinavica*, **2004**, 110, 59-66	3.8	78
138	Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. *Neurology*, **2006**, 66, 529-34	6.5	73
137	Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson Disease. *Cell Reports*, **2016**, 15, 1866-75	8.6	66
136	An update on the potential role of excitotoxicity in the pathogenesis of Parkinson disease. *Functional Neurology*, **2010**, 25, 65-71	2.2	65
135	Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson disease. *Neuroscience Letters*, **2009**, 467, 203-7	3.3	58
134	Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson Disease. *Scientific Reports*, **2016**, 6, 33738	4.9	58
133	Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson disease cells. *Neurobiology of Disease*, **2015**, 82, 235-242	7.5	57
132	Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson disease. *Annals of Neurology*, **2001**, 49, 525-529	9.4	57
131	Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson disease. *Cell Death and Disease*, **2018**, 9, 818	9.8	53
130	New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson disease: targeting glutamate and adenosine receptors. *Expert Opinion on Investigational Drugs*, **2012**, 21, 153-68	5.9	53
129	Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. *Cephalalgia*, **2014**, 34, 594-604	6.1	52
128	Role of Autophagy in Parkinson Disease. *Current Medicinal Chemistry*, **2019**, 26, 3702-3718	4.3	52
127	Implication of limonene and linalyl acetate in cytotoxicity induced by bergamot essential oil in human neuroblastoma cells. *Fitoterap*, **2013**, 89, 48-57	3.2	51
126	Insulin receptor subunit haploinsufficiency impairs hippocampal late-phase LTP and recognition memory. *NeuroMolecular Medicine*, **2012**, 14, 262-9	4.6	51
125	Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats. *European Journal of Neuroscience*, **1997**, 9, 1407-13	3.5	51
124	Peripheral levels of BDNF and NGF in primary headaches. *Cephalalgia*, **2006**, 26, 136-42	6.1	51
123	Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. *Free Radical Biology and Medicine*, **2004**, 36, 1233-40	7.8	51

122	Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. *Journal of Neuroinflammation*, **2016**, 13, 146	10.1	50
121	Intestinal dysmotility and enteric neurochemical changes in a Parkinson disease rat model. *Autonomic Neuroscience: Basic and Clinical*, **2012**, 169, 77-86	2.4	47
120	Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson disease. The effect of dopaminergic treatment. *Journal of Neural Transmission*, **2004**, 111, 1017-30	4.3	47
119	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. *Movement Disorders*, **2019**, 34, 9-21	7	45
118	DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). *Psychopharmacology*, **2004**, 173, 353-63	4.7	44
117	Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson disease, multiple system atrophy and dementia of the Alzheimer type. *Journal of Neural Transmission Parkinsonis Disease and Dementia Section*, **1992**, 4, 191-205		44
116	Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson disease. *Brain Research Bulletin*, **2010**, 82, 29-38	3.9	43
115	Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 1385-94	6.9	42
114	Peripheral markers of oxidative stress in Parkinson disease. The role of L-DOPA. *Free Radical Biology and Medicine*, **1999**, 27, 428-37	7.8	42
113	The Exosomal/Total Synuclein Ratio in Plasma Is Associated With Glucocerebrosidase Activity and Correlates With Measures of Disease Severity in PD Patients. *Frontiers in Cellular Neuroscience*, **2018**, 12, 125	6.1	41
112	Brain monoaminergic neurotransmission parameters in weanling rats after perinatal exposure to methylmercury and 2,2,4,4,5,5-hexachlorobiphenyl (PCB153). *Brain Research*, **2006**, 1112, 91-8	3.7	41
111	Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment. *Headache*, **2012**, 52, 1350-61	4.2	39
110	Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2005**, 1741, 325-30	6.9	39
109	The Involvement of Post-Translational Modifications in Alzheimer Disease. *Current Alzheimer Research*, **2018**, 15, 313-335	3	39
108	Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson disease. *Neurobiology of Disease*, **2006**, 24, 492-505	7.5	38
107	Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson Disease. *Frontiers in Neuroscience*, **2017**, 11, 306	5.1	37
106	Homocysteine and Parkinson disease: a dangerous liaison?. *Journal of the Neurological Sciences*, **2007**, 257, 31-7	3.2	37
105	Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects. *Stem Cells Translational Medicine*, **2015**, 4, 1073-85	6.9	36

104	Enteric Dysfunctions in Experimental Parkinson Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 356, 434-44	4.7	36
103	Prospects of glutamate antagonists in the therapy of Parkinson disease. *Fundamental and Clinical Pharmacology*, **1998**, 12, 4-12	3.1	36
102	Age-related changes of protein SUMOylation balance in the APP Tg2576 mouse model of Alzheimer disease. *Frontiers in Pharmacology*, **2014**, 5, 63	5.6	35
101	Quantitative study of mitochondrial complex I in platelets of parkinsonian patients. *Movement Disorders*, **1998**, 13, 11-5	7	35
100	DNA fragmentation and oxidative stress in the hippocampal formation: a bridge between 3,4-methylenedioxymethamphetamine (ecstasy) intake and long-lasting behavioral alterations. *Behavioural Pharmacology*, **2007**, 18, 471-81	2.4	35
99	Peripheral expression of key regulatory kinases in Alzheimer disease and Parkinson disease. *Neurobiology of Aging*, **2011**, 32, 2142-51	5.6	33
98	Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson disease. *Journal of Molecular Neuroscience*, **2012**, 46, 177-83	3.3	32
97	Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl. *Journal of Neural Transmission Parkinsonis Disease and Dementia Section*, **1991**, 3, 15-25		32
96	Dopamine receptor agonists for Parkinson disease. *Expert Opinion on Investigational Drugs*, **2014**, 23, 387-410	5.9	31
95	A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: effects of nitroglycerin. *International Review of Neurobiology*, **2007**, 82, 373-82	4.4	31
94	Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. *Journal of Chemical Neuroanatomy*, **2004**, 27, 23-32	3.2	31
93	Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia. *Brain Research*, **1995**, 669, 59-66	3.7	31
92	A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline. *Headache*, **1990**, 30, 439-44	4.2	31
91	Peripheral-Central Neuroimmune Crosstalk in Parkinson Disease: What Do Patients and Animal Models Tell Us?. *Frontiers in Neurology*, **2019**, 10, 232	4.1	30
90	Activation of the CREB/ Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer. *Frontiers in Cellular Neuroscience*, **2017**, 11, 184	6.1	30
89	Evolution of prodromal parkinsonian features in a cohort of mutation-positive individuals: a 6-year longitudinal study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 1091-1097	5.5	29
88	Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. *Journal of Neuropathology and Experimental Neurology*, **2014**, 73, 414-24	3.1	29
87	Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors. *Experimental Cell Research*, **2010**, 316, 1148-58	4.2	29

86	Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson disease. *Brain Research*, **2007**, 1176, 53-61	3.7	29
85	Free plasma catecholamine levels in healthy subjects: a basal and dynamic study. The influence of age. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1992**, 52, 9-17	2	29
84	Glucocerebrosidase Defects as a Major Risk Factor for Parkinson Disease. *Frontiers in Aging Neuroscience*, **2020**, 12, 97	5.3	28
83	Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. *Biomedical Applications*, **1997**, 700, 278-82		28
82	Neuroprotection by rasagiline: a new therapeutic approach to Parkinson disease?. *CNS Neuroscience & Therapeutics*, **2005**, 11, 183-94		28
81	Nitroglycerin-induced activation of monoaminergic transmission in the rat. *Cephalalgia*, **2002**, 22, 226-32	6.1	28
80	Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms. *Cephalalgia*, **2017**, 37, 1272-1284	6.1	27
79	Evaluation of ADMA-DDAH-NOS axis in specific brain areas following nitroglycerin administration: study in an animal model of migraine. *Journal of Headache and Pain*, **2015**, 16, 560	8.8	27
78	Activation of brain metabolism and fos during limbic seizures: the role of locus coeruleus. *Neurobiology of Disease*, **2008**, 30, 388-399	7.5	27
77	Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson disease. *Apoptosis: an International Journal on Programmed Cell Death*, **2012**, 17, 289-304	5.4	26
76	Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson disease. *Journal of Neurochemistry*, **2015**, 134, 740-7	6	25
75	Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions. *Neurological Sciences*, **2001**, 22, 49-50	3.5	25
74	Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia. *Brain Research*, **2008**, 1238, 215-23	3.7	24
73	Peripheral markers of apoptosis in Parkinson disease: the effect of dopaminergic drugs. *Annals of the New York Academy of Sciences*, **2003**, 1010, 675-8	6.5	24
72	Toxic profile of bergamot essential oil on survival and proliferation of SH-SY5Y neuroblastoma cells. *Food and Chemical Toxicology*, **2011**, 49, 2780-92	4.7	22
71	Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson disease. *International Journal of Nanomedicine*, **2012**, 7, 435-47	7.3	21
70	Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson disease. *Experimental Neurology*, **2008**, 212, 548-51	5.7	21
69	MDMA induces caspase-3 activation in the limbic system but not in striatum. *Annals of the New York Academy of Sciences*, **2006**, 1074, 377-81	6.5	21

68	Electrophysiological and metabolic effects of CHF5074 in the hippocampus: protection against in vitro ischemia. *Pharmacological Research*, **2014**, 81, 83-90	10.2	20
67	Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson disease. *Neurogastroenterology and Motility*, **2015**, 27, 1783-95	4	20
66	Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson disease: a self-perpetuating crosstalk?. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2012**, 1822, 176-84	6.9	20
65	Selective stimulation of striatal dopamine receptors of the D1- or D2-class causes opposite changes of fos expression in the rat cerebral cortex. *European Journal of Neuroscience*, **2003**, 17, 763-70	3.5	20
64	Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats. *Clinical and Experimental Pharmacology and Physiology*, **2015**, 42, 695-703	3	19
63	Dopaminergic modulation of apoptosis in human peripheral blood mononuclear cells: possible relevance for Parkinson disease. *Annals of the New York Academy of Sciences*, **2003**, 1010, 679-82	6.5	19
62	Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. *Clinical Chemistry*, **2001**, 47, 1102-4	5.5	19
61	Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemia-reperfusion injury. *Journal of Neuroscience Research*, **2018**, 96, 151-159	4.4	17
60	Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. *European Journal of Pharmacology*, **2014**, 744, 91-7	5.3	17
59	Neuroprotective effect of nitroglycerin in a rodent model of ischemic stroke: evaluation of Bcl-2 expression. *International Review of Neurobiology*, **2007**, 82, 423-35	4.4	17
58	Calcium homeostasis is dysregulated in parkinsonian patients with L-DOPA-induced dyskinesias. *Clinical Neuropharmacology*, **2009**, 32, 133-9	1.4	16
57	Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat. *Neurotoxicity Research*, **2017**, 32, 71-81	4.3	15
56	Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: comparative study with conventional in vivo techniques in the rat. *Journal of Pharmacological and Toxicological Methods*, **2014**, 70, 163-9	1.7	15
55	Intrastriatal injection of D1 or D2 dopamine agonists affects glucose utilization in both the direct and indirect pathways of the rat basal ganglia. *Neuroscience Letters*, **2001**, 309, 161-4	3.3	15
54	Combined response of plasma and platelet catecholamines to different types of short-term stress. *Life Sciences*, **1995**, 56, 1113-20	6.8	15
53	Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion. *Neuroscience Letters*, **1995**, 186, 99-102	3.3	15
52	Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias. *Expert Opinion on Investigational Drugs*, **2017**, 26, 777-791	5.9	14
51	Mitochondrial Complex I Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson Disease. *Antioxidants and Redox Signaling*, **2018**, 28, 44-61	8.4	14

50	Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection. *Biomedical Applications*, **1999**, 732, 213-20		14
49	Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. *Neuropharmacology*, **2017**, 123, 22-33	5.5	13
48	A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. *Parkinsonis Disease*, **2012**, 2012, 489857	2.8	13
47	Modulation of RAGE isoforms expression in the brain and plasma of rats exposed to transient focal cerebral ischemia. *Neurochemical Research*, **2012**, 37, 1508-16	4.6	13
46	The influence of gender in the evaluation of platelet and plasma catecholamines. *Life Sciences*, **1993**, 52, 1995-2004	6.8	13
45	Magnetic resonance spectroscopy in Parkinson's disease and parkinsonian syndromes. *Functional Neurology*, **2007**, 22, 75-9	2.2	13
44	Effects of homocysteine on apoptosis-related proteins and anti-oxidant systems in isolated human lymphocytes. *FEBS Journal*, **2004**, 271, 1671-6		12
43	Dopamine receptor agonists mediate neuroprotection in malonate-induced striatal lesion in the rat. *Experimental Neurology*, **2002**, 178, 301-5	5.7	12
42	Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. *Neurobiology of Disease*, **2020**, 139, 104821	7.5	11
41	Subtle alterations of excitatory transmission are linked to presynaptic changes in the hippocampus of PINK1-deficient mice. *Synapse*, **2016**, 70, 223-30	2.4	11
40	Search for cellular stress biomarkers in lymphocytes from patients with multiple sclerosis: a pilot study. *PLoS ONE*, **2012**, 7, e44935	3.7	11
39	Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. *Journal of Neural Transmission*, **2003**, 110, 911-22	4.3	11
38	Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach. *Experimental Neurology*, **2003**, 184, 556-60	5.7	11
37	Potential therapeutic effects of polyphenols in Parkinson's disease: and pre-clinical studies. *Neural Regeneration Research*, **2021**, 16, 234-241	4.5	11
36	Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients. *European Journal of Clinical Pharmacology*, **2012**, 68, 1493-9	2.8	10
35	Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease. *Neurobiology of Disease*, **2011**, 43, 663-8	7.5	10
34	Assay of [3H]dihydrorotenone binding to complex I in intact human platelets. *Analytical Biochemistry*, **1995**, 230, 16-9	3.1	10
33	Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease. *Nutrition*, **2020**, 69, 110494	4.8	10

32	Modulation of cerebral RAGE expression following nitric oxide synthase inhibition in rats subjected to focal cerebral ischemia. *European Journal of Pharmacology*, **2017**, 800, 16-22	5.3	9
31	Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson© disease. *Neurological Sciences*, **2003**, 24, 157-8	3.5	9
30	Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum. *Neurological Sciences*, **2003**, 24, 180-1	3.5	9
29	Effects of etoperidone on sympathetic and pituitary-adrenal responses to diverse stressors in humans. *Clinical Neuropharmacology*, **1993**, 16, 127-38	1.4	9
28	Development and biochemical characterization of a mouse model of Parkinson© disease bearing defective glucocerebrosidase activity. *Neurobiology of Disease*, **2019**, 124, 289-296	7.5	9
27	Facemasks and face recognition: Potential impact on synaptic plasticity. *Neurobiology of Disease*, **2021**, 153, 105319	7.5	7
26	In vivo imaging of early signs of dopaminergic neuronal death in an animal model of Parkinson© disease. *Neurobiology of Disease*, **2018**, 114, 74-84	7.5	6
25	Characterization of gene expression induced by RTN-1C in human neuroblastoma cells and in mouse brain. *Neurobiology of Disease*, **2010**, 40, 634-44	7.5	6
24	Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat. *Brain Research*, **2006**, 1101, 145-50	3.7	6
23	Profiling the Biochemical Signature of GBA-Related Parkinson© Disease in Peripheral Blood Mononuclear Cells. *Movement Disorders*, **2021**, 36, 1267-1272	7	6
22	GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinson© Disease. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
21	Simultaneous assay of platelet and plasma catecholamines by HPLC with coulometric detection. *Chromatographia*, **1993**, 36, 164-166	2.1	5
20	Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson© Disease. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
19	The origin recognition complex subunit, ORC3, is developmentally regulated and supports the expression of biochemical markers of neuronal maturation in cultured cerebellar granule cells. *Brain Research*, **2010**, 1358, 1-10	3.7	4
18	Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: the synergistic role of dopamine. *Journal of Cellular Biochemistry*, **2008**, 103, 877-85	4.7	4
17	Modifications of local cerebral metabolic rates for glucose and motor behavior in rats with unilateral lesion of the subthalamic nucleus. *Journal of Cerebral Blood Flow and Metabolism*, **1999**, 19, 149-54	7.3	4
16	Cardiopressor effects of short-term treatment with cabergoline in L-dopa stable responder parkinsonian patients: relevance of postprandial hypotension. *Clinical Neuropharmacology*, **1991**, 14, 343-51	1.4	4
15	An update on the use of non-ergot dopamine agonists for the treatment of Parkinson© disease. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 2279-2291	4	3

14	In vivo modeling of prodromal stage of Parkinson disease. *Journal of Neuroscience Methods*, **2020**, 342, 108801	3	2
13	Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. *Neurological Sciences*, **2002**, 23 Suppl 2, S57-8	3.5	2
12	Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote synuclein aggregation		2
11	Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson disease. *Cell Death and Differentiation*, **2021**, 28, 1720-1732	12.7	2
10	Fibroblasts from skin biopsies as a tool for biomarker discovery in Parkinson?s disease. *Free Radical Biology and Medicine*, **2014**, 75 Suppl 1, S10	7.8	1
9	Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat. *Experimental Neurology*, **2006**, 200, 240-4	5.7	1
8	Noninvasive neuromodulation in Parkinson disease: Neuroplasticity implication and therapeutic perspectives.. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2022**, 184, 185-198	3	1
7	Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson Disease Patients with GBA Mutations. *Movement Disorders*, **2021**,	7	1
6	Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote synuclein aggregation.. *Brain*, **2022**,	11.2	1
5	A reliable indirect cell-labelling protocol for optical imaging allows ex vivo visualisation of mesenchymal stem cells after transplantation. *Archives Italiennes De Biologie*, **2013**, 151, 114-25	1.1	1
4	Single or combined treatment with L-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells. *Neuroscience Letters*, **2013**, 552, 168-73	3.3	
3	Neuroprotective compounds and innovative therapeutic strategies for Parkinson’s disease: experimental and clinical studies. *Open Access Journal of Clinical Trials*, **2009**, Volume 1, 1-15	1.5	
2	Plasma beta-endorphin, cortisol and norepinephrine responses to physical and metabolic stressors in young and elderly humans. *Stress and Health*, **1992**, 8, 1-9		
1	Reply to: "Increased alpha-Synuclein Level in CD45 Blood Cells in Asymptomatic Carriers of GBA Mutations". *Movement Disorders*, **2021**, 36, 1998-1999	7	